It makes sense, but it is still far too early to verify the accuracy of these rumor pieces — see this from Barron’s — quoting Bloomberg:
. . . .Merck. . . put in first-round offers for diabetes drug maker Amylin Pharmaceuticals, according to sources close to the private negotiations.
As Bloomberg is reporting the bids were for at least $25 a share, valuing the company at more than $4 billion, based on its shares outstanding as of April 26. . . .
An interesting diabetes-space play, if accurate (given Merck’s Januvia/Janumet franchises). Do stay tuned — and have a safe Memorial Day Weekend!